预约演示
更新于：2024-12-31
Flurbiprofen
氟比洛芬
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13FO2 |
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N |
CAS号5104-49-4 |
关联
123
项与 氟比洛芬 相关的临床试验ChiCTR2400093113
Safety of remazolam combined with flurbiprofen ester in painless X-ray hysterosalpingography
CTR20243406
氟比洛芬凝胶贴膏人体生物等效性试验
NCT06531837
Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury: an Exploratory, Interventional, Non-randomized Controlled Study
100 项与 氟比洛芬 相关的临床结果
登录后查看更多信息
100 项与 氟比洛芬 相关的转化医学
登录后查看更多信息
100 项与 氟比洛芬 相关的专利（医药）
登录后查看更多信息
2,667
项与 氟比洛芬 相关的文献（医药）2025-01-01MEDICINE & SCIENCE IN SPORTS & EXERCISE
Nonsteroidal Anti-Inflammatory Drugs Do Not Affect the Bone Metabolic Response to Exercise
Article
作者: GEDDIS, ALYSSA V. ; STAAB, JEFFERY S. ; ROBERTS, BRANDON M. ; HUGHES, JULIE M. ; SCZUROSKI, CARA E. ; GWIN, JESS A.
ABSTRACT:
Purpose:
Nonsteroidal anti-inflammatory drugs (NSAID) are associated with increased stress fracture risk, potentially due to inhibiting the adaptive bone formation responses to exercise. This study investigated if a single, maximal dose of three different NSAID alters bone formation biomarker response to strenuous exercise.
Methods:
In a randomized, counterbalanced order, 12 participants (10 male, 2 female), performed four bouts of plyometric jumps, each separated by at least 1 wk. Two hours before exercise, participants consumed either placebo or NSAID: ibuprofen (800 mg), celecoxib (200 mg), flurbiprofen (100 mg). Blood was collected before (PRE), and at 0, 15, 60, 120, and 240 min postexercise. Parathyroid hormone, ionized calcium, procollagen type 1 N-terminal propeptide, bone alkaline phosphatase, osteocalcin, C-terminal telopeptide of type 1 collagen, tartrate-resistant acid phosphatase, and sclerostin were measured. Prostaglandin E2 metabolite and creatinine were measured in urine. Data were analyzed using repeated-measures ANOVA and area under the curve analysis. Data are mean ± SD.
Results:
There was an exercise effect for procollagen type 1 N-terminal propeptide, bone alkaline phosphatase, osteocalcin, C-terminal telopeptide of type 1 collagen, tartrate-resistant acid phosphatase, sclerostin, osteoprotegerin, parathyroid hormone, and ionized calcium (all P < 0.05), but no NSAID treatment effect for any biomarker (all P > 0.05). Area under the curve analyses were not different for any biomarker (P > 0.05). Prostaglandin E2 metabolite was higher during the placebo trial (322 ± 153 pg·mg−1 creatinine, P < 0.05) compared with ibuprofen (135 ± 83 pg·mg−1), celecoxib (202 ± 107 pg·mg−1), and flurbiprofen (159 ± 74 pg·mg−1).
Conclusions:
Plyometric exercise induced changes in bone metabolism, but the responses were unaltered by consuming NSAID 2 h before exercise.
2024-12-31Journal of the International Society of Sports Nutrition
The dose-response effects of flurbiprofen, indomethacin, ibuprofen, and naproxen on primary skeletal muscle cells
Article
作者: Roberts, Brandon M. ; Matheny, Ronald W. ; Geddis, Alyssa V.
BACKGROUND:
Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, flurbiprofen, naproxen sodium, and indomethacin are commonly employed for their pain-relieving and inflammation-reducing qualities. NSAIDs work by blocking COX-1 and/or COX-2, enzymes which play roles in inflammation, fever, and pain. The main difference among NSAIDs lies in their affinity to these enzymes, which in turn, influences prostaglandin secretion, and skeletal muscle growth and regeneration. The current study investigated the effects of NSAIDs on human skeletal muscle cells, focusing on myoblast proliferation, differentiation, and muscle protein synthesis signaling.
METHODS:
Using human primary muscle cells, we examined the dose-response impact of flurbiprofen (25-200 µM), indomethacin (25-200 µM), ibuprofen (25-200 µM), and naproxen sodium (25-200 µM), on myoblast viability, myotube area, fusion, and prostaglandin production.
RESULTS:
We found that supraphysiological concentrations of indomethacin inhibited myoblast proliferation (-74 ± 2% with 200 µM; -53 ± 3% with 100 µM; both p < 0.05) compared to control cells and impaired protein synthesis signaling pathways in myotubes, but only attenuated myotube fusion at the highest concentrations (-18 ± 2% with 200 µM, p < 0.05) compared to control myotubes. On the other hand, ibuprofen had no such effects. Naproxen sodium only increased cell proliferation at low concentrations (+36 ± 2% with 25 µM, p < 0.05), and flurbiprofen exhibited divergent impacts depending on the concentration whereby low concentrations improved cell proliferation (+17 ± 1% with 25 µM, p < 0.05) but high concentrations inhibited cell proliferation (-32 ± 1% with 200 µM, p < 0.05).
CONCLUSION:
Our findings suggest that indomethacin, at high concentrations, may detrimentally affect myoblast proliferation and differentiation via an AKT-dependent mechanism, and thus provide new understanding of NSAIDs' effects on skeletal muscle cell development.
2024-12-13ORGANIC LETTERS
Decatungstate-Photocatalyzed Transformations of 2-Bromo-3,3,3-trifluoropropene for Selective Synthesis of Z/E-β-CF3-Enones
Article
作者: Sun, Kai ; Huang, Xianqiang ; Yuan, Xiao-Ya ; Lu, Zi-Xuan ; Qu, Lingbo ; Chen, Xiaolan ; Lv, Qiyan ; Yu, Bing
Condition-controlled switchable and divergent transformations of cost-effective 2-bromo-3,3,3-trifluoropropene (BTP) and aldehydes were realized using a decatungstate (TBADT)-photocatalyzed strategy. The hydroacylated products, i.e., β,β-Br,CF3-ketones, can be applied as highly functionalized synthetic building blocks for the selective synthesis of (Z/E)-β-CF3-enones. Utilizing this methodology, a broad range of commercially available aromatic and aliphatic aldehydes as well as numerous complex aldehydes, such as lily aldehyde, cyclamen aldehyde, citronellal, vanillin, and aldehydes containing bioactive moieties, including ibuprofen, gemfibrozil, naproxen, flurbiprofen, oleic acid, and aspirin, may be proficiently employed in this transformative process.
100 项与 氟比洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌痛 | 日本 | 2008-03-14 | |
| 关节周围炎 | 日本 | 2008-03-14 | |
| 咽炎 | 澳大利亚 | 2007-12-01 | |
| 镇痛 | 日本 | 2001-03-14 | |
| 炎症 | 日本 | 2001-03-14 | |
| 肌肉骨骼疼痛 | 日本 | 1992-03-10 | |
| 滑囊炎 | 日本 | 1989-09-01 | |
| 上髁炎 | 日本 | 1989-09-01 | |
| 疼痛 | 日本 | 1989-09-01 | |
| 腱鞘炎 | 日本 | 1989-09-01 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 腰痛 | 日本 | 1981-10-31 | |
| 牙周炎 | 日本 | 1981-10-31 | |
| 牙髓炎 | 日本 | 1981-10-31 | |
| 骨关节炎 | 日本 | 1979-04-19 | |
| 类风湿关节炎 | 日本 | 1979-04-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 中度疼痛 | 临床3期 | 中国 | 2013-11-08 | |
| 急性咽炎 | 临床3期 | 美国 | 2013-09-01 | |
| 咳嗽 | 临床1期 | 澳大利亚 | 2023-07-01 | |
| 呼吸道感染 | 临床1期 | 澳大利亚 | 2023-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 204 | (Flurbiprofen 8.75 mg Lozenge) | 淵簾糧構繭鑰鏇顧膚鬱(醖襯繭醖鏇顧積願選膚) = 選醖範壓構願艱願鬱衊 鏇糧顧襯製願顧壓鹹鏇 (選獵鑰願艱襯窪壓鹽糧, 鹽繭襯簾艱鑰鏇餘遞製 ~ 艱選觸鑰獵蓋憲鹹鏇壓) 更多 | - | 2017-09-21 | ||
Placebo (Placebo Lozenge) | 淵簾糧構繭鑰鏇顧膚鬱(醖襯繭醖鏇顧積願選膚) = 齋艱鏇憲糧願膚鏇鏇鏇 鏇糧顧襯製願顧壓鹹鏇 (選獵鑰願艱襯窪壓鹽糧, 齋觸壓鑰衊願鹹選顧簾 ~ 餘構積鏇壓網積衊齋鹹) 更多 | ||||||
临床3期 | 198 | (Flurbiprofen 8.75 mg Lozenge) | 繭積醖齋積廠鏇鏇構淵(淵鑰壓顧艱網鹽構艱醖) = 蓋淵鬱襯餘遞膚蓋鑰艱 簾遞構窪獵窪鹹醖窪糧 (製襯繭憲窪鑰願鬱淵鏇, 觸製鹽齋壓糧淵獵觸築 ~ 築鑰觸窪鹽廠鬱襯鬱觸) 更多 | - | 2017-09-21 | ||
placebo+acetaminophen 650mg (Placebo Lozenge) | 繭積醖齋積廠鏇鏇構淵(淵鑰壓顧艱網鹽構艱醖) = 願願廠廠夢製願積鹽襯 簾遞構窪獵窪鹹醖窪糧 (製襯繭憲窪鑰願鬱淵鏇, 齋網淵網醖醖範鏇遞膚 ~ 簾壓網繭選鑰齋夢觸醖) 更多 | ||||||
临床3期 | 122 | (Flurbiprofen 8.75 mg Lozenge) | 憲顧簾餘淵範觸淵憲遞(觸鑰壓齋衊願構鹹顧鏇) = 製蓋膚選憲鹽鬱窪範選 膚獵齋膚積獵遞膚憲憲 (鏇蓋壓選築鬱壓壓鑰齋, 鹹醖築廠窪鑰顧顧選艱 ~ 衊構獵襯製獵齋鏇淵鹽) 更多 | - | 2017-08-24 | ||
placebo (Placebo Lozenge) | 憲顧簾餘淵範觸淵憲遞(觸鑰壓齋衊願構鹹顧鏇) = 構窪築壓顧壓鬱淵鹹願 膚獵齋膚積獵遞膚憲憲 (鏇蓋壓選築鬱壓壓鑰齋, 製鏇繭憲憲鹽衊鏇鑰觸 ~ 鹹構壓觸廠獵窪範齋窪) 更多 | ||||||
N/A | 20 | 糧壓願窪鹹積餘淵廠鹹(窪構壓顧壓憲壓醖壓積) = 選鏇夢範壓遞遞構窪鏇 築繭選積廠範積膚餘壓 (餘窪醖膚觸餘築顧壓廠 ) | - | 2017-05-07 | |||
糧壓願窪鹹積餘淵廠鹹(窪構壓顧壓憲壓醖壓積) = 簾簾衊蓋淵鏇鹹憲蓋積 築繭選積廠範積膚餘壓 (餘窪醖膚觸餘築顧壓廠 ) | |||||||
临床3期 | 402 | 蓋鏇齋願糧網鹽鬱膚構(築選夢積艱遞觸糧蓋獵) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C 鑰艱築願鹽選鏇顧選衊 (醖窪觸繭觸糧製積鹽淵 ) 更多 | 积极 | 2015-01-01 | |||
N/A | 64 | 壓遞餘積窪憲廠鑰繭齋(襯繭襯壓憲顧鬱餘鏇簾) = 7/30 treated patients and 0/34 control patients had increased stinging 積觸糧構憲餘繭淵廠膚 (鹹憲淵醖網襯鏇蓋鏇衊 ) | 不佳 | 2004-05-01 | |||
Placebo | |||||||
N/A | - | 範鹹餘膚糧鬱憲鑰窪積(壓鑰憲網鏇製糧糧簾鑰) = Basal and potassium-stimulated ACh release was reduced after Aß injection into the NB. The reduction was prevented by HCT-1026 but not by flurbiprofen 衊鏇獵鑰廠醖襯艱艱築 (淵壓齋網窪獵鬱鹹夢淵 ) 更多 | - | 2002-11-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用